Welcome to BioSeeker Group!

Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight

Additional Information

Published Date Sep 19, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 179
PDF Fact Sheet View Fact Sheet for the report Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight.

    To find out more about Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years. This is most prominent due to the introduction of three novel cytotoxic agents -  Xeloda, Camptosar, and Eloxatin - and the recent approval of the two antibodies - Avastin and Erbitux.

Interestingly, an army of novel agents and targets are currently in Phase II clinical trials, and their contributions and impact on future therapy in colorectal cancer remains to be seen.

 

Scope of this report

  • Thorough examination of status and impact of 70 novel drugs in development
  • Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
  • Case studies on major CRC drugs on market
  • Competitive landscape assessment, including more than 120 companies in the field and high lightening the top twenty competitors

 

Research and analysis highlights

Colorectal cancer has become an excellent tumor model for evaluating new therapeutic strategies. Development of a detailed understanding of how this cancer develops, spreads, and grows allows a tailored approach to all stages of treatment: prevention, adjuvant treatment, and therapy of advanced disease. As a result, specific molecular processes have been targeted for therapeutic intervention, including growth factor receptors, proliferation signaling, cell cycling, apoptosis, angiogenesis, and the immune system.

The anti-VEGF antibody Avastin has in recent clinical trials been shown to be safely and effectively used in combination with each of the active anticancer agents used in CRC. However, the chdevelopment of active combination regimens has not yet achieved any significant improvements in the actual cure rate.

Intense efforts are attempting to identify critical molecular biomarkers that can be used to predict for either clinical response to chemotherapy and/or targeted therapies and/or the drug-specific side effects. This has led the industry into a multitude of collaborations, for them to have the chance to successfully deliver on these issues.

 

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for 70 novel therapeutics in CRC, and the results of clinical trials to date.
  • Novel targets and agents are discussed organized into: Growth factor receptors, Signaling transducers; Apoptopic agents, Anti-vascular agents and Immuno-modulators.
  • Gain insight into the current challenges and commercial opportunities associated with CRC

2 Executive Summary

3 Cancer Highlights

4 Methodology

5 List of Contents

5.1 List of Boxes
5.2 List of Figures
5.3 List of Tables

6 Epidemiology

6.1 Disease Definition
6.2 Prognosis for Colorectal Cancer by Stage

7 Drugs on Market

7.1 A 50% Increase in Sales!
7.2 Topoisomerase inhibitor in First-line and Second-line Treatment
7.3 Fast Way to Approval
7.4 A Significant Reduction in the Risk of Death
7.5 Mice and Men
7.6 The Very Base

8 Key Drug Strategies in CRC

8.1 Apoptosis
8.1.1 An Answer to Drug Resistance
8.1.2 Novel Therapies at the Gate
8.2 Tumor Vascularization & Antivascular Agents
8.2.1 Anti-angiogenesis: Therapeutic Strategies
8.2.2 Single Agent Therapy: Poorly Active in Advanced Tumors.
8.2.3 Synergistic Effects with Cytotoxic Therapies
8.2.4 Vascular Targeting Agents
8.3 Vaccines
8.3.1 Tumor antigens
8.3.2 The Cell Vaccines Strategy
8.3.3 Potent antigen presenting cells
8.3.4 Emerging strategies

9 Competitive Landscape in CRC Drug Development

9.1 We are in the Lead
9.1.1 Amgen
9.1.2 Novartis and Schering
9.1.3 OSI, Genentech, Hoffmann La Roche & Pfizer
9.1.4 Sanofi-Aventis

10 Current CRC Drug Development

10.1 Chemotherapy and Cytotoxic Drugs - A strategy reborn
10.1.1 Progress Analysis: CoFactor
10.1.2 Progress Analysis: Trabectedin (ET-743)
10.1.3 Progress Analysis: Pemetrexed
10.1.4 Progress Analysis: TS-1
10.1.5 Progress Analysis: Edotecarin
10.1.6 Progress Analysis: Aroplatin
10.1.7 Progress Analysis: Ixabepilone
10.2 EGF-R Inhibition and Other Signal Transduction Inhibitors
10.2.1 Progress Analysis: Panitumumab
10.2.2 Progress Analysis: Erlotinib (Tarceva)
10.2.3 Progress Analysis: Gefitinib (Iressa)
10.2.4 Progress Analysis: Pelitinib
10.2.5 Progress Analysis: Sorafenib
10.3 Signal Transduction Inhibitors in CRC
10.3.1 Progress Analysis: BIO-117
10.3.2 Progress Analysis: PD 0325901
10.4 Antiangiogenetic- A team of players
10.4.1 Progress Analysis: Vatalanib
10.4.2 Progress Analysis: Thalidomide
10.4.3 Progress Analysis: AMG 706
10.4.4 Progress Analysis: Combretastatin A4 prodrug
10.4.5 Progress Analysis: MBT 0206
10.4.6 Progress Analysis: MEDI 522
10.4.7 Progress Analysis: Tetrathiomolybdate
10.4.8 Progress Analysis: WX-UK1
10.5 COX-2 Inhibitors - What will become of us?
10.5.1 Progress Analysis: P 54
10.5.2 Progress Analysis: CV-247
10.6 Apoptosis: An approach with a future
10.6.1 Progress Analysis: HGS-ETR1
10.6.2 Progress Analysis: APLIDIN
10.6.3 Progress Analysis: VELCADE
10.6.4 Progress Analysis: TELCYTA
10.6.5 Progress Analysis EPO 906
10.6.6 Progress Analysis: BIO-145
10.6.7 Progress Analysis: Genasense
10.6.8 Progress Analysis: Rexin-G
10.6.9 Progress Analysis: Indisulam
10.6.10 Progress Analysis: Seliciclib
10.6.11 Progress Analysis: SYMADEX
10.7 Necrotic Cell Death Inducers
10.7.1 Progress Analysis: RAV12
10.7.2 Progress Analysis: Cantuzumab mertansine
10.7.3 Progress Analysis: HuC242-DM4
10.7.4 Progress Analysis: COTARA
10.8 Vaccines: A high Threshold to Success
10.8.1 Cell Vaccine
10.8.2 Vaccine: Direct Immunization with Protein and peptides
10.8.3 Anti-idiotype Monoclonal Antibodies
10.8.4 DNA and Virally Encoded Vaccines
10.8.5 Passive Immunotherapy and Conjugated Antibodies
10.9 Immuno-modulators
10.9.1 Progress Analysis: Dacogen
10.9.2 Progress Analysis: GCAN-101
10.9.3 Progress Analysis: ZYC300
10.9.4 Progress Analysis: Clofarabine
10.10 Oncolytic Virotherapy in CRC - A team of four
10.10.1 Progress Analysis: OncoVEX
10.10.2 Progress Analysis: Oncolytic HSV

11 Disclaimer

12 Appendix I: Treatment Guide Lines

12.1.1 Medical Therapy of Colorectal Cancer

13 Appendix II: Selected Company Profiles

14 Drug Index

15 Company Index

5.1 List of Boxes

Box 1:Example of Observed Efficacy in preclinical models
Box 2: Anti-angiogenesis: Therapeutic strategies.
Box 3: Anti-angiogenesis: Problems that has to be solved
Box 4: Mechanisms which tumor cells use to evade an immune reaction
Box 5: Quick Facts - ANX-510
Box 6: Quick Facts - Trabectedin
Box 7: Quick Facts - Pemetrexed
Box 8: Quick Facts - TS-1
Box 9: Quick Facts - Edotecarin
Box 10: Quick Facts - Aroplatin
Box 11: Quick Facts - Ixabepilone
Box 12: Quick Facts - Panitumumab
Box 13: Quick Facts - Erlotinib
Box 14: Scientific Data on Erlotinib
Box 15: Quick Facts - Gefitinib
Box 16: Scientific Data on Gefitinib
Box 17: Quick Facts - Pelitinib
Box 18: Quick Facts - Sorafenib
Box 19: Quick Facts - BIO-117
Box 20: Quick Facts - PD 0325901
Box 21: Quick Facts - Vatalanib
Box 22: Quick Facts - Thalomide
Box 23: Quick Facts - AMG 706
Box 24: Quick Facts - Combretastatin
Box 25: Quick Facts - MBT 0206
Box 26: Quick Facts - MEDI 522
Box 27: Quick Facts - Tetrathiomolybdate
Box 28: Quick Facts - WX-UK1
Box 29: Quick Facts - P 54
Box 30: Quick Facts - CV-247
Box 31: Targets for Apoptosis Directed Therapy
Box 32: Selection of Patents Relating to Apoptosis
Box 33: Quick Facts - HGS-ETR1
Box 34: Quick Facts - APLIDIN
Box 35: Quick Facts - VELCADE
Box 36: Millenniums License Agreement with Ortho Biotech
Box 37: Quick Facts - TELCYTA
Box 38: Quick Facts - EPO 906
Box 39: Quick Facts - BIO-145
Box 40: Quick Facts - Genasense
Box 41: Quick Facts - Rexin-G
Box 42: Quick Facts - Indisulam
Box 43: Quick Facts - Seliciclib
Box 44: Quick Facts - SYMANDEX
Box 45: Quick Facts - RAV12
Box 46: Quick Facts - Cantuzumab mertansine
Box 47: Quick Facts - HuC242-DM4
Box 48: Quick Facts - Cotara
Box 49: Quick Facts - OncoVAX
Box 50: Quick Facts - Canvaxin
Box 51: Quick Facts - Collidem
Box 52: Quick Facts - Dendricell
Box 53: Quick Facts - Neuvenge
Box 54: Quick Facts - Onyvax-CR
Box 55: Quick Facts - Ras-VAX
Box 56: Quick Facts - Avicine
Box 57: Quick Facts - Oncophage
Box 58: Quick Facts - EP 2101
Box 59: Quick Facts - MSI Vaccine
Box 60: Quick Facts - MUC-vaccine
Box 61: Quick Facts - OncoVAX
Box 62: Quick Facts - CeaVac
Box 63: Quick Facts - Onyvax-105
Box 64: Quick Facts - TroVax
Box 65: Quick Facts - ALVA-CEA-B7.1
Box 66: Quick Facts - CEA-TRICOM
Box 67: Quick Facts - IR 705
Box 68 Quick Facts - Amplivax
Box 69: Quick Facts - IGN 101
Box 70: Quick Facts - CEA-Cide
Box 71: Quick Facts - LMB 9
Box 72: Quick Facts - KSB 303
Box 73: Quick Facts - ING-1
Box 74: Quick Facts -Dacogen
Box 75: Quick Facts - GCAN-101
Box 76: Quick Facts - ZYC300
Box 77: Quick Facts - Clofarabine
Box 78: Quick Facts - OncoVEX
Box 79: Quick Facts - NV 1020

5.2 List of Figures

5.3 List of Tables

Table 1: 5-year Survival Rate in CRC
Table 2: Risk Factors for Colon Cancer Development
Table 3: Summary of Colorectal Cancer Regimens
Table 4: Summary of Chemotherapy Drugs
Table 5: Capecitabine - Major Developmental Milestones
Table 6: Ironotecan - Major Developmental Milestones
Table 7: Bevacizumab - Major Developmental Milestones
Table 8: Sales Predictions on Bevacizumab
Table 9: Oxaliplatin - Major Developmental Milestones
Table 10: Cetuximab - Major Developmental Milestones
Table 11: Sales Predictions on Cetuximab
Table 12: Common Gene/Protein Defects in Apoptotic Pathways
Table 13: A Selection of Apoptosis Targets in Development
Table 14: Selection of VTA agents under clinical development as cancer therapeutics
Table 15: Colorectal Cancer Vaccines in Development
Table 16: The Representation of Investigators in the CRC Drug Pipeline
Table 17: Drugs with Four or more Investigators
Table 18: Phase III Competitors
Table 19: Industrial Investigators with the Highest Number of CRC Drugs in Phase I to Phase III development
Table 20: Phase I -Phase III Chemotherapy and Cytotoxic Drugs in Development
Table 21: Phase I-Phase III EGF-R Inhibitors as CRC Therapeutics
Table 22: Phase I-Phase III Signal Transduction Inhibitors in CRC
Table 23: Phase I - Phase III Antiangiogenic Drugs in Development
Table 24: Current COX-2 Inhibitors in Development
Table 25: Apoptotic Cell Death Inducers in Development
Table 26: Necrotic Cell Death Inducers in Development
Table 27 Cell therapy based platform in pipeline as potential treatment of colorectal cancer
Table 28: Protein/peptide vaccine as potential treatment of colorectal cancer
Table 29: Anti-idiotype monoclonal antibodies
Table 30: Nucleic acid and virally encoded vaccines
Table 31: Monoclonal Antibodies
Table 32: Immuno-modulators in CRC

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight.
    To find out more about Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Cancer Vaccines Fantasy or Future?
In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements. Learn More


Prostate Cancer - A Therapeutic & Competitive Insight
In this report BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. Learn More

Other selected research from the 'R&D' category:


IL-1 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More


Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update
BioSeeker Group have identified 529 companies plus partners who are today developing 854 cytokine-cytokine receptor interaction interference drugs in 2473 developmental projects in cancer across 310 different targets. In addition, there are 10 suspended drugs and another 303 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


IL-5 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More


Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 182 companies plus partners who are today developing 255 Fc epsilon RI signaling pathway targeting drugs in 966 developmental projects in cancer across 148 different targets. In addition, there are 2 suspended drugs and another 84 drugs where development has been ceased. Learn More